MoonLake Immunotherapeutics (MLTX) Balance Sheet
As of 2026-06-30 (10-Q), MoonLake Immunotherapeutics (MLTX) reported total assets of $573.9M, total liabilities of $145.8M and shareholders' equity of $428.2M, according to EquiReason's reading of its SEC filings. Cash and equivalents: $477.9M. Long-term debt: $99.5M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
MLTXMoonLake ImmunotherapeuticsFollow MLTX — free
—
Price chart with a free account
- Market cap
- 1.0B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 17 Nov, in 24 days
| Line | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | Latest Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 1.3 | 8.0 | 39.5 | 451.2 | 180.4 | 334.5 | 477.9 | |
| Short-term investments | — | 0.0 | 32.6 | 59.8 | 267.6 | 59.5 | 59.1 | |
| Current assets | 1.6 | 9.6 | 76.5 | 514.2 | 474.3 | 421.7 | 570.0 | |
| Total assets | 116.6 | 9.7 | 76.8 | 526.5 | 477.9 | 424.4 | 573.9 | |
| Current liabilities | 0.1 | 21.1 | 7.7 | 10.0 | 22.5 | 45.5 | 45.4 | |
| Long-term debt | — | — | — | — | 0.0 | 74.1 | 99.5 | |
| Short-term debt | — | 15.0 | 0.0 | — | — | — | — | |
| Total liabilities | 4.2 | 21.3 | 8.1 | 13.0 | 24.5 | 120.0 | 145.8 | |
| Shareholders' equity | -2.5 | -11.6 | 48.9 | 495.7 | 446.8 | 304.5 | 428.2 |
USD millions · SEC XBRL
MoonLake Immunotherapeutics — questions
- How much cash does MoonLake Immunotherapeutics have?
- $477.9M in cash and cash equivalents as of 2026-06-30.
- How much debt does MoonLake Immunotherapeutics have?
- $99.5M of long-term debt as of 2026-06-30.
- What are MoonLake Immunotherapeutics's total assets?
- $573.9M as of 2026-06-30.
- What is MoonLake Immunotherapeutics's shareholders' equity?
- $428.2M as of 2026-06-30.
Every figure on this page comes from MoonLake Immunotherapeutics's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.